See more : InterDigital, Inc. (IDCC) Income Statement Analysis – Financial Results
Complete financial analysis of CV Sciences, Inc. (CVSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CV Sciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BioPharma Credit PLC (BPCP.L) Income Statement Analysis – Financial Results
- AXP Energy Limited (AXP.AX) Income Statement Analysis – Financial Results
- GWG Holdings, Inc. (GWGHQ) Income Statement Analysis – Financial Results
- Samvardhana Motherson International Limited (MOTHERSON.NS) Income Statement Analysis – Financial Results
- Reinsurance Group of America, Incorporated (RGA) Income Statement Analysis – Financial Results
CV Sciences, Inc. (CVSI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cvsciences.com
About CV Sciences, Inc.
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00M | 16.21M | 20.05M | 24.43M | 53.70M | 48.24M | 20.68M | 11.06M | 11.53M | 10.19M | 2.15M | 0.00 | 0.00 |
| Cost of Revenue | 8.92M | 10.66M | 11.43M | 13.42M | 18.61M | 14.37M | 6.19M | 4.06M | 4.42M | 4.39M | 880.47K | 0.00 | 0.00 |
| Gross Profit | 7.09M | 5.55M | 8.62M | 11.01M | 35.09M | 33.88M | 14.49M | 7.00M | 7.11M | 5.80M | 1.27M | 0.00 | 0.00 |
| Gross Profit Ratio | 44.27% | 34.25% | 42.98% | 45.07% | 65.35% | 70.22% | 70.06% | 63.27% | 61.65% | 56.95% | 59.13% | 0.00% | 0.00% |
| Research & Development | 151.00K | 307.00K | 1.19M | 2.94M | 5.88M | 1.89M | 724.33K | 1.16M | 1.32M | 999.28K | 524.48K | 0.00 | 0.00 |
| General & Administrative | 6.55M | 3.89M | 13.93M | 19.36M | 34.39M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 0.00 | 88.09K |
| Selling & Marketing | 2.94M | 8.20M | 11.95M | 11.30M | 12.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.49M | 12.09M | 25.88M | 30.66M | 46.45M | 21.75M | 16.25M | 13.13M | 17.75M | 13.36M | 2.37M | 43.02K | 88.09K |
| Other Expenses | -5.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -12.27K | -8.55K | -73.21K | -34.82K | 0.00 | 43.02K | 0.00 |
| Operating Expenses | 3.73M | 12.40M | 27.06M | 33.60M | 52.33M | 23.63M | 16.98M | 13.91M | 19.07M | 14.36M | 2.89M | 43.02K | 88.09K |
| Cost & Expenses | 12.64M | 23.05M | 38.49M | 47.02M | 70.94M | 38.00M | 23.17M | 17.97M | 23.50M | 18.74M | 3.77M | 43.02K | 88.09K |
| Interest Income | 0.00 | 1.54M | 140.00K | 9.00K | 15.00K | 0.00 | 2.00 | 27.66K | 18.29K | 30.70K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.54M | 140.00K | 9.00K | 0.00 | 153.00K | 506.38K | 1.09M | 968.62K | 615.34K | 372.11K | 2.59K | 2.09K |
| Depreciation & Amortization | 235.00K | 1.06M | 1.50M | 1.47M | 1.53M | 519.00K | 182.00K | 1.05M | 1.01M | 933.60K | 767.25K | 43.02K | 0.00 |
| EBITDA | 3.85M | -5.66M | -14.00M | -21.72M | -15.69M | 10.77M | -4.69M | -12.00M | -10.25M | 236.99K | -1.16M | -2.59K | -88.09K |
| EBITDA Ratio | 24.03% | -36.13% | -86.26% | -88.91% | -30.77% | 22.32% | -11.21% | -52.80% | -95.49% | -75.19% | -39.46% | 0.00% | 0.00% |
| Operating Income | 3.36M | -6.85M | -18.45M | -22.59M | -17.24M | 10.25M | -4.86M | -13.07M | -11.21M | -8.55M | -1.62M | -43.02K | -88.09K |
| Operating Income Ratio | 20.99% | -42.25% | -92.01% | -92.48% | -32.11% | 21.24% | -23.50% | -118.20% | -97.23% | -83.93% | -75.08% | 0.00% | 0.00% |
| Total Other Income/Expenses | -264.00K | -1.41M | 2.81M | -9.00K | 15.00K | -153.00K | -519.00K | -1.07M | -1.02M | 7.24M | -682.86K | -2.59K | -2.09K |
| Income Before Tax | 3.10M | -8.26M | -15.64M | -22.60M | -17.23M | 10.09M | -5.38M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Income Before Tax Ratio | 19.35% | -50.98% | -78.02% | -92.52% | -32.08% | 20.92% | -26.01% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| Income Tax Expense | -6.00K | -47.00K | -87.00K | -317.00K | -615.00K | 93.00K | -481.50K | 1.08M | 895.40K | 541.98K | 372.11K | -43.02K | 0.00 |
| Net Income | 3.10M | -8.21M | -15.55M | -22.28M | -16.61M | 10.00M | -4.90M | -14.14M | -12.23M | -1.31M | -2.30M | -45.61K | -90.18K |
| Net Income Ratio | 19.38% | -50.69% | -77.58% | -91.22% | -30.93% | 20.73% | -23.68% | -127.85% | -106.10% | -12.87% | -106.78% | 0.00% | 0.00% |
| EPS | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.06 | -0.14 | -0.22 | -0.17 | 0.09 | -0.06 | -0.27 | -0.35 | -0.04 | -0.23 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 153.95M | 138.03M | 107.82M | 99.91M | 97.86M | 111.12M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
| Weighted Avg Shares Out (Dil) | 153.96M | 138.03M | 107.82M | 99.91M | 97.86M | 114.47M | 80.43M | 52.66M | 35.14M | 31.58M | 9.88M | 7.00M | 6.97M |
CV Sciences, Inc. (CVSI) Reports Q2 Loss, Tops Revenue Estimates
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q2 2021 Results - Earnings Call Transcript
CV Sciences, Inc. Reports Second Quarter 2021 Financial Results
CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award
CBD Can Reduce Nicotine Withdrawal Symptoms, Says New Study Done By CV Sciences
Cantor Updates Ratings On Several Cannabis And CBD Stocks - MedMen, Jushi, cbdMD, CV Sciences
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2021 Results - Earnings Call Transcript
Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know
CV Sciences and Alkemist Labs Form Partnership to Support the National Institute of Standards and Technology's Cannabis Quality Assurance Program
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q4 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports